RxDoctor Payments Data

James Dailey, DO

Family Medicine · Joplin, MONPI 1730120759

Payments from drug & device makers

$10,483in general payments, 2019–2025

Across 499 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$2K
  • AbbVie$1K
  • Novo Nordisk$784
  • Pfizer$745
  • Boehringer Ingelheim$572
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$10,434100%
  • Education$490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,483 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$106,194
Medicare patients
392
Services billed
2,517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$108,493
JardianceEmpagliflozin94$101,241
OzempicSemaglutide35$38,828
TrulicityDulaglutide25$38,394
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$37,926
FarxigaDapagliflozin Propanediol42$37,193
LinzessLinaclotide32$30,098
XareltoRivaroxaban33$29,313
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$26,518
Spiriva RespimatTiotropium Bromide35$20,117
MyrbetriqMirabegron40$19,997
Breo ElliptaFluticasone/Vilanterol38$19,386
JanuviaSitagliptin Phosphate13$18,380
MounjaroTirzepatide17$17,445
VraylarCariprazine Hcl11$15,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$572$121,359129 claims
PfizerEliquis, Abrysvo$745$116,651136 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,932$77,727119 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arexvy$559$64,859117 claims
Lilly USA, LLCTrulicity, Mounjaro$328$55,83942 claims
AbbVieLinzess, Vraylar, Creon$1,392$54,36660 claims
Novo NordiskOzempic$784$38,82835 claims
Johnson & JohnsonXarelto$139$29,31333 claims
Astellas Pharma US IncMyrbetriq$73$19,99740 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$35$3,30422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →